NMD4C Wraps up Second Year of Training Series for Canadian Neuromuscular Clinical Fellows
We’re excited to share that the second annual National Neuromuscular Lecture Series (NNLS) finished last week! The NNLS is our 38-week virtual curriculum for neuromuscular fellows, developed by the Pillar 3 curriculum and education team together with the directors of fellowship programs across Canada. In total, 32 fellows participated in this year’s lecture series, including adult and pediatric neuromuscular and physiatry fellows from programs across Canada.
Thank-you to this year’s NNLS lead Dr. Alberto Aleman, and all the moderators who helped conduct these lectures: Drs. Hernan Gonorazky, Jessica Thériault, Erin O’Ferrall, Marianne Nury, Alasdair Rathbone, Amanda Yaworski, and Mona Hnaini. We would also like to extend a thank-you to and share our appreciation of the speakers who presented during the program, and all the fellows who participated. We look forward to hosting the third annual curriculum beginning this August!
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.